Zomedica Pharma (ZOM) has released an update.
Zomedica Corp. is actively engaging with NYSE American to address compliance issues after failing to meet listing standards, despite shareholders rejecting a proposed 80:1 reverse stock split. The company’s stock will remain listed as it works on measures to improve its share price and leverage its progress and future prospects to avoid delisting. Zomedica specializes in veterinary health products for animals and is committed to enhancing their care through innovative diagnostics and devices.
For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.
